1.10. Analysis.
Comparison 1 RISPERIDONE vs PLACEBO, Outcome 10 Adverse effects: 1c. extrapyramidal ‐ skewed data (various scales) ‐ short term (up to 12 weeks).
Adverse effects: 1c. extrapyramidal ‐ skewed data (various scales) ‐ short term (up to 12 weeks) | ||||
---|---|---|---|---|
Study | Intervention | Mean | SD | N |
average change score of AIMS | ||||
Potkin 2006 | Risperidone | 0.3 | 2.47 | 153 |
Potkin 2006 | Placebo | ‐0.1 | 2.56 | 73 |
average change score of CGI severity dyskinesia | ||||
Chouinard 1992 | Risperidone | 0.3 | 3.3 | 22 |
Chouinard 1992 | Placebo | 3.5 | 5.3 | 22 |
average change score of CGI severity parkinsonism | ||||
Chouinard 1992 | Risperidone | 0.9 | 1.5 | 22 |
Chouinard 1992 | Placebo | 0.4 | 1.3 | 22 |
average change score of ESRS | ||||
Marder 1994a | Risperidone | 2.9 | 5.7 | 63 |
Marder 1994a | Placebo | 2.4 | 5.8 | 65 |
average change score of ESRS ‐ akathisia | ||||
Marder 1994a | Risperidone | 0.6 | 1.1 | 63 |
Marder 1994a | Placebo | 0.6 | 1.6 | 65 |
average change score of ESRS ‐ dystonia | ||||
Chouinard 1992 | Risperidone | 0.3 | 0.8 | 22 |
Chouinard 1992 | Placebo | 1.0 | 2.3 | 22 |
Marder 1994a | Risperidone | 1.3 | 1.3 | 63 |
Marder 1994a | Placebo | 1.6 | 1.5 | 64 |
Pai 2002 | Risperidone | 2.1 | 1.7 | 22 |
Pai 2002 | Placebo | 2.8 | 1.8 | 20 |
average change score of ESRS ‐ dyskinesia | ||||
Chouinard 1992 | Risperidone | 2.6 | 4.5 | 22 |
Chouinard 1992 | Placebo | 5.7 | 7.2 | SD |
Marder 1994a | Risperidone | 0.6 | 1.1 | 63 |
Marder 1994a | Placebo | 0.5 | 1.1 | 65 |
average change score of ESRS ‐ parkinsonism | ||||
Chouinard 1992 | Risperidone | 2.1 | 7.5 | 22 |
Chouinard 1992 | Placebo | 2.3 | 8.7 | 22 |
Marder 1994a | Risperidone | 0.6 | 1.1 | 63 |
Marder 1994a | Placebo | 0.5 | 1.1 | 65 |
Pai 2002 | Risperidone | 2.1 | 1.3 | 22 |
Pai 2002 | Placebo | 2.5 | 1.5 | 20 |